SG10201709101VA - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer

Info

Publication number: SG10201709101VA
Authority: SG; Singapore
Prior art keywords: cancer; compositions; treatment; methods
Prior art date: 2013-05-07

Application number

SG10201709101VA

Inventor

Laura Soucek

Marie-Eve Beaulieu

Original Assignee

Fundació Privada Inst D'investigació Oncològica De Vall Hebron

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-07

Filing date

2014-05-07

Publication date

2017-12-28

2014-05-07 Application filed by Fundació Privada Inst D'investigació Oncològica De Vall Hebron filed Critical Fundació Privada Inst D'investigació Oncològica De Vall Hebron

2017-12-28 Publication of SG10201709101VA publication Critical patent/SG10201709101VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Marine Sciences & Fisheries (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

SG10201709101VA 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer SG10201709101VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP20130382167 EP2801370A1 (en)	2013-05-07	2013-05-07	Methods and compositions for the treatment of cancer

Publications (1)

Publication Number	Publication Date
SG10201709101VA true SG10201709101VA (en)	2017-12-28

Family

ID=48366303

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201709101VA SG10201709101VA (en)	2013-05-07	2014-05-07	Methods and compositions for the treatment of cancer
SG11201509131VA SG11201509131VA (en)	2013-05-07	2014-05-07	Methods and compositions for the treatment of cancer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201509131VA SG11201509131VA (en)	2013-05-07	2014-05-07	Methods and compositions for the treatment of cancer

Country Status (26)

Country	Link
US (2)	US10370434B2 (en)
EP (4)	EP2801370A1 (en)
JP (2)	JP6722103B2 (en)
KR (1)	KR102324116B1 (en)
CN (1)	CN105378084B (en)
AU (1)	AU2014264642B2 (en)
BR (2)	BR122020017819B1 (en)
CA (1)	CA2911863A1 (en)
CY (1)	CY1121849T1 (en)
DK (1)	DK2994533T3 (en)
EA (2)	EA035463B1 (en)
ES (1)	ES2733515T3 (en)
HK (1)	HK1251494A1 (en)
HR (1)	HRP20191330T1 (en)
HU (1)	HUE045615T2 (en)
IL (2)	IL242483B (en)
LT (1)	LT2994533T (en)
ME (1)	ME03509B (en)
MX (1)	MX370792B (en)
PL (1)	PL2994533T3 (en)
PT (1)	PT2994533T (en)
RS (1)	RS59276B1 (en)
SG (2)	SG10201709101VA (en)
SI (1)	SI2994533T1 (en)
SM (1)	SMT201900423T1 (en)
WO (1)	WO2014180889A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2801370A1 (en)	2013-05-07	2014-11-12	Fundació Privada Institut d'Investigació Oncològica de Vall Hebron	Methods and compositions for the treatment of cancer
WO2017136534A1 (en)	2016-02-03	2017-08-10	Kennesaw State University Researcha And Service Foundation, Inc.	Signal molecules as cell penetration agents
WO2017190061A1 (en) *	2016-04-29	2017-11-02	The University Of Chicago	Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en)	2016-07-15	2018-01-17	Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron	Methods and compositions for the treatment of cancer
CN106591335A (en) *	2016-11-08	2017-04-26	安徽省农业科学院水稻研究所	Codon vegetalization-transformed LbCpf1 gene and application thereof
EP3678679A1 (en) *	2017-09-08	2020-07-15	IDP Discovery Pharma, S.L.	New treatments of multiple myeloma
US20200354411A1 (en) *	2017-11-29	2020-11-12	Agency For Science, Technology And Research	Chimeric Molecule for Targeting c-Myc in Cells
CN112513297B (en)	2018-03-28	2024-10-22	得克萨斯州大学系统董事会	Identification of epigenetic changes in DNA isolated from exosomes
WO2019199803A1 (en) *	2018-04-09	2019-10-17	Board Of Regents, The University Of Texas System	Therapeutic targeting of oncogenes using exosomes
CN113557035B (en) *	2019-01-12	2025-09-05	卫理公会医院	Self-assembling peptide nanoparticles and their uses
TWI829893B (en) *	2019-03-19	2024-01-21	瓦爾希伯倫私人腫瘤研究基金會	Methods for the diagnosis of lung cancer
WO2020187998A1 (en) *	2019-03-19	2020-09-24	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
CN114174313A (en)	2019-04-09	2022-03-11	芝加哥大学	Macrocyclization and multimerization of peptides and proteins of the general type using diels-alder cycloaddition
KR102221227B1 (en)	2019-05-07	2021-03-03	김영화	Shopping mall platform providing apparatus with supplier interrelationship and multilingual supporting function and method thereof
WO2021041953A1 (en) *	2019-08-30	2021-03-04	The Regents Of The University Of California	Gene fragment overexpression screening methodologies, and uses thereof
CN115925975B (en) *	2022-08-03	2024-09-17	山东大学	A method for preparing CAR-MΦ in vivo and in vitro editing targeting tumor stem cells and its application
EP4361633A1 (en)	2022-10-25	2024-05-01	Peptomyc, S.L.	Method for predicting response to a cancer treatment
EP4446742A1 (en)	2023-04-14	2024-10-16	Peptomyc, S.L.	Method for assessing or monitoring the response to a cancer treatment
WO2025064985A1 (en) *	2023-09-22	2025-03-27	Ohio State Innovation Foundation	Myc INHIBITOR PROTEINS AND USES THEREOF
CN118557561A (en) *	2024-05-16	2024-08-30	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	9-Hexadecenoic acid in preparation of product for preventing and treating colorectal tumor and application of product as synergist of chemotherapeutic medicine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (en)	1980-11-10	1985-04-15	Gersonde Klaus Prof Dr	PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS.
EP0088046B1 (en)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipids in the aqueous phase
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US5322801A (en)	1990-04-19	1994-06-21	The General Hospital Corporation	Protein partner screening assays and uses thereof
WO1993019176A1 (en)	1992-03-23	1993-09-30	Imperial Cancer Research Technology Limited	Leucine zippers
EP1342781A1 (en) *	2002-03-09	2003-09-10	ARTEMIS Pharmaceuticals GmbH	Recombinase fusion protein with enhanced cellular uptake
GB0413730D0 (en)	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
US8735394B2 (en) *	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
JP5855568B2 (en) *	2009-09-15	2016-02-09	セルリアン・ファーマ・インコーポレイテッド	Cancer treatment
DE102009052866A1 (en) *	2009-11-13	2011-05-19	Bizerba Gmbh & Co. Kg	cutting machine
WO2011097522A2 (en)	2010-02-05	2011-08-11	Whitehead Institute For Biomedical Research	Combination methods for treatment of disease
RU2556800C2 (en)	2010-06-14	2015-07-20	Ф.Хоффманн-Ля Рош Аг	Cell-penetrating peptides and thereof application
US9241920B2 (en) *	2011-10-27	2016-01-26	New York University	Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (en)	2013-05-07	2014-11-12	Fundació Privada Institut d'Investigació Oncològica de Vall Hebron	Methods and compositions for the treatment of cancer

2013
- 2013-05-07 EP EP20130382167 patent/EP2801370A1/en not_active Withdrawn
2014
- 2014-05-07 JP JP2016512358A patent/JP6722103B2/en active Active
- 2014-05-07 EA EA201690159A patent/EA035463B1/en unknown
- 2014-05-07 LT LTEP14722204.6T patent/LT2994533T/en unknown
- 2014-05-07 BR BR122020017819-1A patent/BR122020017819B1/en active IP Right Grant
- 2014-05-07 CN CN201480032555.2A patent/CN105378084B/en active Active
- 2014-05-07 BR BR112015028115-0A patent/BR112015028115B1/en active IP Right Grant
- 2014-05-07 ME MEP-2019-203A patent/ME03509B/en unknown
- 2014-05-07 ES ES14722204T patent/ES2733515T3/en active Active
- 2014-05-07 DK DK14722204.6T patent/DK2994533T3/en active
- 2014-05-07 SG SG10201709101VA patent/SG10201709101VA/en unknown
- 2014-05-07 WO PCT/EP2014/059315 patent/WO2014180889A1/en not_active Ceased
- 2014-05-07 HR HRP20191330TT patent/HRP20191330T1/en unknown
- 2014-05-07 SM SM20190423T patent/SMT201900423T1/en unknown
- 2014-05-07 HU HUE14722204A patent/HUE045615T2/en unknown
- 2014-05-07 CA CA2911863A patent/CA2911863A1/en active Pending
- 2014-05-07 RS RSP20190840 patent/RS59276B1/en unknown
- 2014-05-07 US US14/889,656 patent/US10370434B2/en active Active
- 2014-05-07 AU AU2014264642A patent/AU2014264642B2/en active Active
- 2014-05-07 EP EP14722204.6A patent/EP2994533B1/en active Active
- 2014-05-07 EA EA202090683A patent/EA202090683A3/en unknown
- 2014-05-07 PT PT14722204T patent/PT2994533T/en unknown
- 2014-05-07 SI SI201431286T patent/SI2994533T1/en unknown
- 2014-05-07 PL PL14722204T patent/PL2994533T3/en unknown
- 2014-05-07 KR KR1020157034532A patent/KR102324116B1/en active Active
- 2014-05-07 MX MX2015015518A patent/MX370792B/en active IP Right Grant
- 2014-05-07 EP EP18153052.8A patent/EP3338789A1/en active Pending
- 2014-05-07 SG SG11201509131VA patent/SG11201509131VA/en unknown
- 2014-05-07 EP EP19172033.3A patent/EP3545966A1/en active Pending
2015
- 2015-11-05 IL IL242483A patent/IL242483B/en active IP Right Grant
2018
- 2018-08-31 HK HK18111179.0A patent/HK1251494A1/en unknown
2019
- 2019-02-22 JP JP2019030931A patent/JP6790148B2/en active Active
- 2019-06-06 US US16/433,438 patent/US11339205B2/en active Active
- 2019-07-26 CY CY20191100800T patent/CY1121849T1/en unknown
2020
- 2020-03-05 IL IL273090A patent/IL273090B/en unknown

Also Published As

Publication number	Publication date
EA035463B1 (en)	2020-06-19
IL273090B (en)	2022-06-01
EA202090683A2 (en)	2020-06-30
EP3338789A1 (en)	2018-06-27
SI2994533T1 (en)	2019-09-30
JP6790148B2 (en)	2020-11-25
ME03509B (en)	2020-04-20
EP2994533A1 (en)	2016-03-16
CN105378084B (en)	2019-07-05
BR112015028115A2 (en)	2017-10-17
MX2015015518A (en)	2016-07-21
JP2019147792A (en)	2019-09-05
US11339205B2 (en)	2022-05-24
WO2014180889A8 (en)	2015-06-18
US20190382468A1 (en)	2019-12-19
IL273090A (en)	2020-04-30
AU2014264642B2 (en)	2020-09-17
LT2994533T (en)	2019-08-12
US10370434B2 (en)	2019-08-06
HK1219756A1 (en)	2017-04-13
RS59276B1 (en)	2019-10-31
HK1251494A1 (en)	2019-02-01
US20160122415A1 (en)	2016-05-05
SG11201509131VA (en)	2015-12-30
CN105378084A (en)	2016-03-02
EA201690159A1 (en)	2016-05-31
BR122020017819B1 (en)	2023-11-21
SMT201900423T1 (en)	2019-09-09
EA202090683A3 (en)	2020-09-30
PT2994533T (en)	2019-08-05
KR20160013058A (en)	2016-02-03
EP3545966A1 (en)	2019-10-02
CY1121849T1 (en)	2020-07-31
JP6722103B2 (en)	2020-07-15
DK2994533T3 (en)	2019-07-01
ES2733515T3 (en)	2019-11-29
MX370792B (en)	2020-01-08
EP2994533B1 (en)	2019-05-01
PL2994533T3 (en)	2020-03-31
IL242483B (en)	2020-03-31
JP2016520056A (en)	2016-07-11
HUE045615T2 (en)	2020-01-28
EP2801370A1 (en)	2014-11-12
BR112015028115B1 (en)	2023-11-21
KR102324116B1 (en)	2021-11-11
WO2014180889A1 (en)	2014-11-13
HRP20191330T1 (en)	2019-10-18
AU2014264642A1 (en)	2015-11-19
CA2911863A1 (en)	2014-11-13

Publication	Publication Date	Title
IL273090B (en)	2022-06-01	Methods and compositions for the treatment of cancer
IL245281A0 (en)	2016-06-30	Methods and compositions for treating cancer
SG11201601412XA (en)	2016-03-30	Compositions and methods for the treatment of presbyopia
IL239453B (en)	2020-03-31	Compositions and methods for treatment of cancer using bacteria
GB201320723D0 (en)	2014-01-08	Composition and methods of treatment
EP2958936A4 (en)	2016-11-09	Methods and compositions for treatment of forbes-cori disease
IL238177A0 (en)	2015-05-31	Methods and compositions for the treatment of cancer
IL246280A0 (en)	2016-07-31	Therapeutic methods and compositions
EP3004396A4 (en)	2017-03-01	Methods and compositions for the treatment of cancer
SG11201508878WA (en)	2015-11-27	Methods of treating cancer
EP3004395A4 (en)	2017-01-04	Compositions and methods for treating cancer
SG11201510300RA (en)	2016-01-28	Compositions and methods for treating skin
PL2968478T3 (en)	2019-01-31	Compositions and methods for the treatment of carboxyhemoglobinemia
ZA201507762B (en)	2017-09-27	Methods of treating cancer
GB201403083D0 (en)	2014-04-09	Treatment of cancer
IL245998A0 (en)	2016-07-31	Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
EP2984185A4 (en)	2017-01-25	Methods and compositions for treating cancer
PL3016948T3 (en)	2017-10-31	2-acylaminothiazoles for the treatment of cancer
WO2014160368A9 (en)	2014-12-11	Compositions and methods for treating cancer
GB201322346D0 (en)	2014-02-05	Combination treatment of cancer
AU2014315422A1 (en)	2015-03-12	Rilyazine derivatives and compositions for the treatment of cancer
GB201322347D0 (en)	2014-02-05	Treatment of cancer
GB201318742D0 (en)	2013-12-04	Treatment of cancer
GB201308529D0 (en)	2013-06-19	Treatment of cancer
GB201305020D0 (en)	2013-05-01	Treatment of cancer